What is PCOS’s new name PMOS?

PCOS renamed to PMOS

Polycystic ovary syndrome (PCOS) has been renamed polyendocrine metabolic ovarian syndrome (PMOS) after a years-long effort by women’s health experts and patient advocates, with the goal of making the condition’s full scope clearer and improving how it’s understood and treated.

The main change is conceptual: the new name is intended to reflect that the condition involves multiple endocrine and metabolic processes—not solely the ovaries—and to address decades of confusion and misdiagnosis that followed from the older label.

Stories around the change frame PMOS as more scientifically accurate and as potentially reducing stigma. Because PCOS has often been perceived as mainly a gynecological problem, that framing can affect care pathways, research priorities, and how clinicians evaluate symptoms that overlap with metabolic health issues.

What matters for patients and clinicians is the messaging and care implication. The renaming is meant to encourage a broader assessment approach—one that treats the hormonal and metabolic aspects together rather than focusing narrowly on ovarian findings.

The reports also emphasize that the condition affects a large share of women globally (with one story citing about 1 in 8 women), making the stakes for effective recognition and management high.

However, the news coverage provided here focuses on the nomenclature shift and its intended clinical and social impact rather than detailing specific new treatments or formal guideline updates.

Bottom line: PMOS is PCOS with a re-label designed to better match the biology and to push care toward a more complete, endocrine-metabolic understanding of the condition.